Breathing is something most people take for granted until it becomes a struggle. For millions around the globe, respiratory conditions like asthma, chronic obstructive pulmonary disease (COPD), and other lung disorders turn simple tasks into daunting challenges.

According to the World Health Organization, over 339 million people were affected by asthma in 2020, and in 2019, COPD was the third leading cause of death globally. These alarming statistics highlight the urgent need for effective treatment options to help those afflicted by chronic respiratory conditions.

Bronchodilators emerge as crucial medications that ease respiratory symptoms by relaxing airway muscles and making breathing easier. This article will explore the different types of bronchodilators, as well as their uses, benefits, and potential side effects. Understanding these medications helps patients and caregivers make informed decisions for better respiratory management and improved quality of life.

Key Findings:

  • Bronchodilators are classified into short-acting and long-acting forms.
  • The three main types of bronchodilators are beta-2 adrenergic agonists, anticholinergics, and theophylline. Each type works through different mechanisms to help patients breathe more easily and manage symptoms of asthma and COPD.
  • Theophylline is used as a second- or third-line treatment for respiratory conditions, and it requires careful monitoring due to its narrow therapeutic window and potential serious side effects.
  • Combining two different bronchodilators or bronchodilators with corticosteroids offers more comprehensive management of respiratory symptoms.

What Are Bronchodilators Used For

What Are Bronchodilators Used For

Bronchodilators are a class of medications designed to relax the muscles around the airways, resulting in the dilation (widening) of the bronchial tubes (airways) within the lungs. This action helps to alleviate symptoms such as shortness of breath, wheezing, and chest tightness by improving airflow to the lungs.

They are commonly used to treat respiratory conditions, including:

  • Asthma: Characterized by chronic inflammation of the airways, leading to episodes of wheezing, breathlessness, chest tightness, and coughing. During an asthma attack, the muscles around the airways tighten (bronchoconstriction), and the lining of the airways becomes swollen and inflamed, producing excess mucus.
  • Chronic Obstructive Pulmonary Disease (COPD): A group of lung diseases, including chronic bronchitis and emphysema, that cause obstructed airflow from the lungs. Symptoms include persistent cough, mucus production, and breathlessness.
  • Allergic Reactions: Severe allergic reactions, such as anaphylaxis, can cause swelling of the airways, leading to difficulty breathing.
  • Bronchitis: A condition that involves inflammation of the bronchial tubes, leading to coughing and mucus production. It can be acute (short-term) or chronic (long-term).
  • Exercise-Induced Bronchoconstriction (EIB): EIB is a temporary narrowing of the airways that occurs during or after exercise, leading to shortness of breath, wheezing, and coughing.

What Are The Types Of Bronchodilators

Different Types Of Bronchodilators

There are two primary forms of bronchodilators. Short-acting bronchodilators quickly relieve symptoms caused by an asthma attack or bronchospasm. Long-acting bronchodilators work to prevent symptoms of asthma attacks and bronchospasms for up to 12 hours. These drugs do not provide immediate relief for ongoing symptoms but help keep airways open throughout the day, reducing the risk of symptoms.

The types of bronchodilator drugs within these forms are as follows.

Beta-2 (?2) Adrenergic Agonists

This type of bronchodilator mimics the effects of catecholamines (epinephrine, norepinephrine, and dopamine), influencing the body’s autonomic responses. Beta-2 agonists bind to beta-2 adrenergic receptors located on the surface of various cells, including those in the airway smooth muscle. This binding activates a series of reactions.

Firstly, it increases the levels of a molecule called cyclic adenosine monophosphate (cAMP) inside the cells. The rise in intracellular cAMP levels then activates another molecule called protein kinase A (PKA), which modifies certain proteins, including ones that help control muscle contraction. These modified proteins then send signals that reduce calcium levels inside the muscle cells. Calcium is essential for muscle contraction, so less calcium means the muscles are less likely to contract.

With lower calcium levels, the contraction of airway smooth muscle is inhibited, leading to relaxation and bronchodilation. This is the primary therapeutic effect of beta-2 agonists, which is beneficial in treating respiratory conditions.

Beta-2 agonists are classified into the following categories:

1. Short-acting beta-agonists (SABAs)

SABAs are often called “rescue” medications for quickly relieving asthma symptoms and attacks because they work fast to open up the airways. They are often used along with other medications like long-acting beta-2 agonists (LABAs), inhaled corticosteroids (ICS), or long-acting muscarinic agonists to manage COPD.

The most commonly used SABA is albuterol (AccuNeb, Proventil HFA, ProAir HFA, Ventolin Diskus), which takes effect in less than 5 minutes and maintains its therapeutic benefits for 4 to 6 hours. Other SABAs include:

  • Terbutaline (Brethine, Bricanyl, Brethaire)
  • Levalbuterol (Xopenex, Xopenex HFA)
  • Pirbuterol (Maxair, Maxair Autohaler)

SABAs are used no more than twice a week to manage shortness of breath. If someone finds themselves needing to use these medications more frequently, it is a sign of poorly controlled asthma.

2. Long-acting beta-agonists (LABAs)

LABAs take a bit longer to start working, up to 15 minutes, but their effects last at least 12 hours. They are typically added to the treatment plan when SABAs and ICS alone are not enough to control asthma symptoms. Common LABAs include:

  • Salmeterol (Serevent Diskus)
  • Formoterol (Foradil Aerolizer, Perforomist)

According to the American Academy of Allergy, Asthma, & Immunology (AAAAI), LABAs should only be combined with corticosteroids to treat asthma. While LABAs have demonstrated benefits such as improved lung function, symptom relief, and enhanced quality of life, evidence indicates that their long-term use as a standalone treatment has been associated with an increase in severe asthma events, including hospitalizations, intubations, and even deaths.

The current consensus in the medical literature supports the safety and efficacy of using LABAs in combination with ICS over monotherapy. Reflecting this, the FDA endorsed the safety of dual therapy for asthma patients in 2017 and issued warnings against the use of LABA monotherapy due to associated risks.

3. Ultra-long-acting beta-agonists (ULABAs)

ULABAs provide prolonged bronchodilation effects, typically lasting for 24 hours. Due to their long duration of action, they are taken once daily, which helps improve patient adherence and convenience. Examples of ULABAs are:

  • Indacaterol (Arcapta Neohaler)
  • Olodaerol (Striverdi Respimat)
  • Vilanterol (usually used in combination with other drugs)

A network meta-analysis evaluating monotherapy with LABAs and ULABAs for individuals with COPD found that indacaterol was the most effective beta-agonist for moderate-to-severe COPD. This was based on its superior impact on spirometry measures, reduction in breathlessness, and lower rates of COPD exacerbations compared to other beta-agonists.


Anticholinergics are a broad class of drugs that inhibit the action of acetylcholine, a neurotransmitter, in the nervous system. Acetylcholine is known to contribute to bronchoconstriction and airway remodeling, including:

  • Goblet Cell Metaplasia: This is a condition where the cells that produce mucus (goblet cells) increase in number or change in a way that leads to more mucus production.
  • Airway Smooth Muscle Thickening: The muscles around the airways become thicker, which can make the airways narrower and harder to breathe through.
  • Extracellular Matrix Deposition: This involves the buildup of extra proteins and other substances around the cells in the airways, which can make the airways stiffer and less flexible.

In treating respiratory conditions, anticholinergics specifically block the action of acetylcholine at muscarinic receptors, which are found in various organs, including the lungs, bladder, gastrointestinal tract, and heart.

There are five subtypes of muscarinic receptors, but M1, M2, and M3 receptors play significant roles in the airways. By targeting these receptors and blocking acetylcholine signaling, anticholinergics help relax the muscles around the airways and decrease mucus production.

Like beta-agonists, anticholinergic or muscarinic antagonist bronchodilators are also classified into categories. These are:

1. Short-acting muscarinic antagonists (SAMAs) or short-acting anticholinergics (SAACs)

Ipratropium bromide, introduced in 1974, is the primary SAMA used in the US. Its duration of action is similar to that of SABAs, which is approximately six hours. However, ipratropium takes longer to start working, with an onset time of 15-30 minutes. The maximum bronchodilation effect, which is the full opening of the airways, can take up to 90 minutes to achieve in people with COPD.

2. Long-acting muscarinic antagonists (LAMAs) or long-acting anticholinergics (LAACs)

LAMAs specifically target the M1 and M3 receptors, which are involved in causing the airways to constrict and produce mucus. It quickly leaves the M2 receptors, which helps to avoid unnecessary side effects.

Because LAMAs bind to the M3 receptors for longer periods, they keep the airways open for a full day with just one dose. This is different from older medications like ipratropium, which needed to be taken three to four times a day. Examples are:

Experts compared the effects of tiotropium with ipratropium bromide. They found that tiotropium significantly improved lung function and reduced the risk of serious adverse events, including hospital admissions, compared to ipratropium. Additionally, tiotropium users had better quality of life scores, experienced fewer exacerbations, and had fewer withdrawals from the study.


Theophylline is used as a second-line treatment for asthma and COPD. However, in many industrialized countries, it has become a third-line option, primarily used as an add-on therapy for patients with poorly controlled symptoms.

Several molecular mechanisms have been proposed to explain how theophylline works, though its exact site of action remains uncertain. One mechanism suggests that theophylline inhibits the synthesis of tumor necrosis factor-alpha (TNF-alpha) and leukotrienes, both of which play roles in inflammatory responses. By reducing inflammation in the airways, theophylline helps alleviate symptoms.

Another proposed mechanism is that theophylline enhances calcium uptake in diaphragmatic muscles, increasing their contraction force. This effect can improve respiratory muscle function, which is particularly beneficial in conditions like COPD, where breathing is compromised.

Unlike beta-agonists and anticholinergics, theophylline is only available in a long-acting form. It is marketed under several brand names, including:

  • Theo-24
  • Theo-Dur
  • Theolair
  • Uniphyl
  • Quibron-T
  • Quibron-TSR
  • Elixophyllin

They are available in various forms, such as extended-release tablets, capsules, solutions, and elixirs, ensuring different options for administration based on patient needs and preferences.

What Are Bronchodilator Combinations

Differenct Asthma Medications

These combinations usually consist of two different types of bronchodilators or a bronchodilator combined with another type of medication, such as a corticosteroid. The goal is to provide more comprehensive management of respiratory symptoms by utilizing the complementary mechanisms of action of the different drugs. Here are some common types of bronchodilator combinations:

1. Long-acting beta-agonists (LABAs) and Inhaled Corticosteroids (ICS) Combinations

LABAs relax the muscles around the airways, making breathing easier, while ICS reduces inflammation within the airways, helping to control symptoms over the long term. Available ICS/LABA therapy includes:

A recent meta-analysis analyzed 54 randomized controlled trials involving 57,333 patients to assess the effectiveness of ICS- containing combination therapies compared to non-ICS therapies for various outcomes in patients with respiratory conditions.

The study demonstrated that ICS-containing combination therapy significantly reduces the risk of exacerbations in patients, with a 14% lower risk compared to non-ICS therapy. It also showed a 22% reduction in the annual rate of exacerbations and a 31% decrease in exacerbations requiring hospitalization. Furthermore, ICS/LABA therapy improved lung function, as indicated by a modest increase in trough FEV1 compared to LABA alone.

Related Reading

Curious about the differences between fluticasone (an inhaled corticosteroid) and albuterol (a beta-agonist bronchodilator)?

Read our blog post on Flovent (fluticasone) vs Albuterol. This article explores the unique benefits, uses, and side effects of Flovent and Albuterol, providing you with the information you need to choose the right inhaler for your needs.

2. Long-acting beta-agonists (LABAs) and Long-acting muscarinic antagonists (LAMAs) Combinations

LABAs and LAMAs both result in bronchodilation but through a different pathway. Several LABA/LAMA combination therapies are available in the market. These include:

  • Vilanterol/Umeclidinium (Anoro Ellipta)
  • Olodaterol/Tiotropium (Stiolto Respimat)
  • Formoterol/Glycopyrrolate (Bevespi Aerosphere)
  • Formoterol/Aclidinium (Duaklir Pressair)
  • Indacaterol/Glycopyrrolate (Utibron Neohaler)

A study compared the effectiveness and safety of LABA/LAMA and LABA/ICS combination therapies. While both treatment combinations were similarly effective in preventing COPD exacerbations, the LABA/LAMA combination had a lower association with severe pneumonia, making it a potentially safer option in clinical practice.

3. Short-acting beta-agonists (SABAs) and Short-acting muscarinic antagonists (SAMAs) Combinations

SABAs provide quick relief by relaxing the muscles around the airways, and SAMAs work similarly but are more effective in blocking the receptors that contribute to bronchoconstriction and mucus production. This combination therapy is marketed under brands like Combivent Respimat (Ipratropium/Albuterol) and DuoNeb (Ipratropium/Albuterol).

A 2006 meta-analysis of seven randomized controlled trials assessed the efficacy of SABA monotherapy versus SABA/SAMA combination therapy in patients with stable COPD. The study found that those treated with the combination therapy showed a significant increase in FEV1 levels, indicating improved lung function, compared to those on SABA monotherapy.

Recently, experts revealed that the combination of ipratropium bromide (SAMA) and salbutamol (SABA) appears to be more effective than salbutamol alone for treating asthma in children and adolescents, particularly in those with severe and moderate-to-severe asthma exacerbations.

4. Triple Combinations (ICS/LABA/LAMA)

These combinations offer the benefits of all three types of medications, anti-inflammatory effects from ICS, bronchodilation from LABAs, and additional bronchodilation from LAMAs. Examples are Breztri Aerosphere (budesonide/glycopyrrolate/formoterol fumarate) and Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol).

In a 2018 study, it was found that triple therapy (ICS/LABA/LAMA) was more effective than LAMA, ICS/LABA, or LAMA/LABA in reducing the risk of exacerbations and improving lung function and health status. The benefit-to-risk ratio was favorable, with minimal risk of side effects, including pneumonia.

Additionally, triple therapy showed potential for improved survival rates. This evidence supports the use of triple therapy as the most effective treatment for moderate to severe COPD patients who are at risk of exacerbations.

These combinations are part of standard treatment regimens to help control symptoms, reduce exacerbations, and improve overall lung function in patients with asthma and COPD. Each combination has specific indications, dosing regimens, and formulations that cater to different patient needs and preferences?.

Related Reading

For a detailed comparison of two popular inhaler options, check out our blog post: Trelegy vs Advair: Which Inhaler is Right for You? This article will discuss the differences, benefits, and potential side effects of Trelegy and Advair, helping you make an informed decision about your respiratory health. Don’t miss this insightful read!

Side Effects Of Bronchodilators

While bronchodilators are generally effective, they can have side effects. These side effects can vary depending on the type of bronchodilator and the specific medication used.

Beta-2 Adrenergic Agonists

Beta-2 agonists can cause various side effects, primarily involving the cardiac, metabolic, or musculoskeletal systems. The most common side effects are:

1. Cardiac Effects

  • Tachycardia: The body’s response to the drug causes an increased heart rate, especially during the first few weeks of use, due to the widening of blood vessels and reduced blood flow back to the heart.
  • Arrhythmias: More common with older generation beta-2 agonists, such as fenoterol, and in patients with heart disease or those using theophylline.
  • Cardiac Toxicity: This includes cardiomyopathy and ischemia and is more strongly correlated with older beta-2 agonists.

2. Metabolic Effects

  • Hypokalemia: Beta-agonists reduce the amount of potassium in the blood (a condition known as hypokalemia) because more potassium is transported into the cells.
  • Elevated Serum Glucose: This results from increased glycogenolysis, which is the process of breaking down glycogen into glucose.

3. Musculoskeletal Effects

  • Tremors: More common with oral beta-2 agonists.

The severity of these side effects depends on the selectivity of the beta-2 agonist for its receptor and the dosage used. Additionally, hypoxemia and hypercapnia can exacerbate the cardiotoxic effects.


Both tiotropium and ipratropium require careful monitoring and consideration of patient-specific factors, especially concerning underlying health conditions and potential drug interactions. Common adverse effects of tiotropium bromide are:

1. Respiratory Issues

  • Pharyngitis, Bronchitis, and Sinusitis: These are frequently reported, potentially due to the medication’s local effects on the respiratory tract.
  • Cough: Another common respiratory-related side effect.

2. Mouth and Throat

  • Dry Mouth: Often experienced by patients on tiotropium.
  • Headaches: Commonly reported alongside other CNS-related symptoms.

The following side effects have also been reported with the use of tiotropium, though they occur less frequently:

  • insomnia, blurry vision, and cataracts
  • epistaxis and rhinitis
  • laryngitis and dysphagia
  • gingivitis
  • chest pain and palpitations
  • joint swelling
  • abdominal pain
  • gastroesophageal reflux disease (GERD)
  • paralytic ileus (in severe cases)
  • abnormal liver function test
  • dysuria and urinary retention
  • angioedema
  • dry skin
  • herpes zoster
  • dehydration

The adverse reactions that have been reported with the use of inhaled ipratropium encompass a range of symptoms and conditions, including but not limited to:

  • xerostomia (dry mouth)
  • skin flushing
  • dyspnea
  • symptoms of a common cold, including sinusitis and bronchitis
  • dizziness
  • back pain
  • nausea
  • urinary tract infections (UTI)
  • tachycardia

Conversely, the side effects associated with the use of intranasal ipratropium include:

  • upper respiratory infections
  • epistaxis
  • pharyngitis
  • throat and nasal irritation
  • headache
  • xerostomia
  • dysgeusia
  • nausea
  • hypersensitivity and anaphylaxis
  • arrhythmias


Theophylline has a very narrow therapeutic window, necessitating careful monitoring of serum concentrations to avoid toxicity. The risk of adverse effects increases significantly when plasma concentrations exceed 20 mg/L, though some patients may experience side effects even at lower concentrations. Common side effects of theophylline include:

1. Gastrointestinal Issues

  • Nausea and Vomiting: These are frequently reported and are related to elevated theophylline levels.
  • Increased Stomach Acid Secretion and Gastroesophageal Reflux: These symptoms can be attributed to the inhibition of phosphodiesterase (PDE).

2. Central Nervous System (CNS) Symptoms

  • Irritability, Lightheadedness, and Dizziness: These can occur even at therapeutic levels and may indicate the onset of toxicity.
  • Seizures (in severe cases): High serum concentrations can lead to convulsions due to adenosine A1-receptor antagonism.

3. Cardiovascular Issues

  • Cardiac Arrhythmias: These can be life-threatening and are a significant concern at high plasma concentrations of theophylline.

Due to these potential side effects and the narrow margin between therapeutic and toxic doses, theophylline use requires careful dose titration and regular monitoring of serum levels to maintain efficacy while minimizing risks?.

Administration of Bronchodilators

Bronchodilators can be administered through inhalers, nebulizers, oral tablets, or injections, depending on the specific medication and the patient’s needs.

Beta-2 Adrenergic Agonists

Beta-2 agonists can be given to patients in several ways, including:

  • Metered dose inhalers (MDIs)
  • Nebulizers
  • Dry powder inhalers (DPIs)
  • Orally

Inhalation is the preferred method for treating asthma and COPD. This is because inhaling the drug directs it straight to the lungs, focusing the treatment on the airway muscles and reducing its spread through the rest of the body. The effectiveness of inhaled beta-2 agonists does not depend on the level of the drug in the bloodstream. Oral administration of beta-2 agonists is less common because it tends to cause more side effects throughout the body.


Anticholinergics are primarily administered via inhalation to treat respiratory conditions. Here are the typical methods of administration:

  • Metered-Dose Inhaler (MDI): Ipratropium is available in an inhaler form, which delivers a specific dose of the medication with each puff.
  • Nebulizer Solution: Ipratropium can be used in a nebulizer, which converts the liquid medication into a fine mist that can be inhaled through a mask or mouthpiece.
  • Nasal Spray: For nasal conditions like allergic rhinitis, Ipratropium is available as a nasal spray.
  • Dry Powder Inhaler (DPI): Tiotropium is commonly available in a DPI form, where the medication is inhaled as a dry powder.
  • Soft Mist Inhaler (SMI): Tiotropium is also available in an SMI, which delivers the medication as a fine mist, providing a more consistent delivery of the drug.


Theophylline is available in various oral forms, including rapid and slow-release tablets, solutions, syrups, and capsules. While rapid-release tablets show wide plasma concentration fluctuations and are less recommended, sustained-release formulations offer a steadier plasma concentration over 12 to 24 hours. These should be taken consistently with or without food to maintain consistent serum drug levels.

The choice of administration method depends on the patient’s preference, the severity of the condition, and the specific recommendation of the healthcare provider.

Final Thoughts

Understanding the various bronchodilator types is important for effectively managing respiratory conditions. Each type of bronchodilator works differently to help patients breathe more easily, and being aware of their uses, benefits, and potential side effects allows for better-informed treatment decisions.

Beta-2 (?2) adrenergic agonists are widely used bronchodilators, providing rapid relief by quickly relaxing airway muscles. Anticholinergics block acetylcholine, preventing airway muscle contraction and offering effective long-term control of COPD symptoms. Theophylline, though less common, reduces airway inflammation and constriction over time and is used when other treatments fall short. However, Theophylline requires regular blood monitoring due to its narrow therapeutic range and potentially serious side effects like nausea, headaches, and arrhythmias.

Recognizing the differences between these bronchodilators allows patients and healthcare providers to tailor treatment plans to individual needs, enhancing overall quality of life.

Get your Bronchodilator for less at Pharma Giant!

At Pharma Giant, you can save up to 90% on prescription medications such as Albuterol. Plus, you can enjoy additional discounts and offers when ordering larger quantities. To save more, use the coupon code FIRST10 for a 10% discount on your first order. Pharma Giant promises expedited delivery, with medications typically arriving within 3-5 business days.

Frequently Asked Questions

What is a natural bronchodilator?

A natural bronchodilator is a substance found in nature that can help relax the muscles of the airways and improve breathing. Examples include caffeine, found in coffee and tea, which has mild bronchodilating properties, and certain herbs like eucalyptus and ginger, which may help reduce inflammation and open up the airways. However, while these natural remedies can offer some relief, they are not substitutes for prescribed bronchodilator medications.

Is a bronchodilator a steroid?

Not all bronchodilators are steroids. Bronchodilators are a broad category of medications designed to relax the muscles around the airways, making breathing easier. They can be classified into short-acting and long-acting types, including beta-agonists and anticholinergics. Steroids, on the other hand, are anti-inflammatory medications that reduce inflammation in the airways. Some respiratory treatments combine bronchodilators with steroids to provide both muscle relaxation and inflammation reduction.

Do I need a prescription for bronchodilators?

Yes, most bronchodilators require a prescription from a healthcare provider. This is because bronchodilators are powerful medications that must be used under medical supervision to ensure they are safe and effective for your specific condition.

Can bronchodilators be used during pregnancy?

Bronchodilators can be used during pregnancy, but it is important to consult with a healthcare provider to ensure the medication is safe for both the mother and the unborn child. Some bronchodilators are considered safer than others, and a doctor can provide guidance based on individual health needs.

How do bronchodilators interact with other medications?

Bronchodilators can interact with various medications, including beta-blockers, diuretics, and certain antidepressants. It’s crucial to inform your healthcare provider about all medications you are taking to avoid adverse interactions.

Are there any dietary restrictions while taking bronchodilators?

Generally, there are no specific dietary restrictions when using bronchodilators. However, some patients might experience increased heart rate or jitteriness, and reducing caffeine intake could help minimize these side effects.

Can children use bronchodilators?

Yes, bronchodilators can be prescribed for children, but the dosage and type of bronchodilator may differ from those used by adults. Pediatric use should always be supervised by a healthcare professional.

Can bronchodilators cause dependency or tolerance?

There is no evidence that bronchodilators cause dependency. However, overuse of short-acting bronchodilators can lead to tolerance, meaning higher doses are needed for the same effect. Long-term management should be guided by a healthcare provider.

How should bronchodilators be stored?

Bronchodilators should be stored at room temperature, away from direct sunlight and moisture. Always check the storage instructions on the packaging and keep medications out of reach of children.

Are there any lifestyle changes that can enhance the effectiveness of bronchodilators?

Maintaining a healthy lifestyle, including regular exercise, a balanced diet, avoiding smoking, and managing stress, can enhance the effectiveness of bronchodilators and overall respiratory health.

Are there any activities I should avoid while using bronchodilators?

While using bronchodilators, avoid activities that can trigger asthma or COPD symptoms, such as exposure to smoke, pollutants, or allergens. Also, consult with a healthcare provider about strenuous exercise if you experience exercise-induced symptoms.


Hsu, E., & Bajaj, T. (2023). Beta2-Agonists. StatPearls – NCBI Bookshelf. Retrieved from

Burkes, R. M., & Panos, R. J. (2020). Ultra Long-Acting ?-Agonists in Chronic Obstructive Pulmonary Disease. Journal of experimental pharmacology, 12, 589–602.

Beta2-Agonists defined | AAAAI. (n.d.). Retrieved from,-asthma-immunology-glossary/beta2-agonists-defined

Lanes, S. F., Lanza, L. L., & Wentworth, C. E., 3rd (1998). Risk of emergency care, hospitalization, and ICU stays for acute asthma among recipients of salmeterol. American journal of respiratory and critical care medicine, 158(3), 857–861.

Research, C. F. D. E. A. (2018). FDA Drug Safety Communication: FDA review finds no significant increase in risk of serious asthma outcomes with long-acting beta agonists (LABAs) used in combination with inhaled corticosteroids (ICS). U.S. Food And Drug Administration. Retrieved from

Donohue, J. F., Betts, K. A., Du, E. X., Altman, P., Goyal, P., Keininger, D. L., Gruenberger, J. B., & Signorovitch, J. E. (2017). Comparative efficacy of long-acting ?2-agonists as monotherapy for chronic obstructive pulmonary disease: a network meta-analysis. International journal of chronic obstructive pulmonary disease, 12, 367–381.

Gosens, R., & Gross, N. (2018). The mode of action of anticholinergics in asthma. The European respiratory journal, 52(4), 1701247.

Cheyne, L., Irvin-Sellers, M. J., & White, J. (2015). Tiotropium versus ipratropium bromide for chronic obstructive pulmonary disease. Cochrane Library, 2015(9).

Jilani, T. N., Preuss, C. V., & Sharma, S. (2023). Theophylline. StatPearls – NCBI Bookshelf.

Suissa, S., Dell’Aniello, S., & Ernst, P. (2019). Comparative Effectiveness and Safety of LABA-LAMA vs LABA-ICS Treatment of COPD in Real-World Clinical Practice. Chest, 155(6), 1158–1165.

Vanfleteren, L., Fabbri, L. M., Papi, A., Petruzzelli, S., & Celli, B. (2018). Triple therapy (ICS/LABA/LAMA) in COPD: time for a reappraisal. International journal of chronic obstructive pulmonary disease, 13, 3971–3981.

Xu, H., Tong, L., Gao, P., Hu, Y., Wang, H., Chen, Z., & Fang, L. (2021). Combination of ipratropium bromide and salbutamol in children and adolescents with asthma: A meta-analysis. PloS one, 16(2), e0237620.

Alexander, V., Henry, J., Vega, S., & Kruger, C. (2021). In patients with stable COPD, is a short-acting beta agonist alone as effective for controlling symptoms as a SABA plus a short-acting muscarinic antagonist? Evidence-based Practice, 24(10), 32.

Ding, Y., Sun, L., Wang, Y., Zhang, J., & Chen, Y. (2022). Efficacy of ICS versus Non-ICS Combination Therapy in COPD: A Meta-Analysis of Randomised Controlled Trials. International journal of chronic obstructive pulmonary disease, 17, 1051–1067.